Suggested remit: To appraise the clinical and cost effectiveness of icotrokinra within its marketing authorisation for moderate to severe plaque psoriasis in people 12 years and over.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6579
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6579:
- 10 November 2025 - 08 December 2025
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2025 | In progress. Scoping commencing |
| 02 October 2025 | To appraise the clinical and cost effectiveness of Icotrokinra within its marketing authorisation for treating plaque psoriasis ID6579 |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual